Treatment with nafamostat mesilate, an NF-κB inhibitor, significantly decreases the volume and weight of nude mice xenografts derived from pancreatic cancer cells compared with the control group [23]. This evidence concerns the gene NFKB1 and familial pancreatic carcinoma.